(the "Company" or "DeFi Technologies") (CBOE CA: DEFI) (GR: R9B), a financial technology company bridging the gap between traditional capital markets and decentralized finance ("DeFi"),  and its ...

Researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital will participate ...

The U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for CAP-002, Capsida Biotherapeutics’ first-in-class, intravenously (IV) administered gene therapy for ...

Dan Booth, from Stoke-on-Trent, said his son Charlie was diagnosed with STXBP1 disorder, a neurological condition, after suffering seizures as a baby. Since then, he said the family had been ...

STXBP1-DEE is estimated to affect up to one in 26,000 births globally, equating to approximately 5,000 pediatric patients in U.S. and Europe. The STXBP1 protein is present in every neuron and is ...

administered investigational gene therapy for syntaxin-binding protein 1 developmental and epileptic encephalopathy (STXBP1-DEE). These data were the foundation for the Investigational New Drug ...

administered investigational gene therapy for syntaxin-binding protein 1 developmental and epileptic encephalopathy (STXBP1-DEE). These data were the foundation for the Investigational New Drug (IND) ...

Following the IND clearance, the Thousand Oaks, California-based firm announced Monday that it is starting preparatory activities for a Phase I/IIa clinical trial, dubbed SYNRGY, and is expecting to ...